Journal for ImmunoTherapy of Cancer (Nov 2020)

388 Preliminary results from KEYNOTE-A36, a study of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab or chemotherapy in specified advanced solid tumors

  • Jack Li

DOI
https://doi.org/10.1136/jitc-2020-SITC2020.0388
Journal volume & issue
Vol. 8, no. Suppl 3

Abstract

Read online

No abstracts available.